A Francisella tularensis Live Vaccine Strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge

Infection and Immunity

Volumn 78, Issue 10, 2010, Pages 4341-4355

  Jia, Qingmei ^a   Lee, Bai Yu ^a   Bowen, Richard ^b   Dillon, Barbara Jane ^a   Som, Susan M ^a   Horwitz, Marcus A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; LIVE VACCINE;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL VIRULENCE; BIOSYNTHESIS; CAPB GENE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FRANCISELLA TULARENSIS; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNITY; IMMUNIZATION; LETHAL DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SPLEEN; SURVIVAL RATE; TULAREMIA; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL VACCINES; CELL LINE; FEMALE; FRANCISELLA TULARENSIS; GENE DELETION; GENETIC MARKERS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULINS; INJECTIONS, INTRADERMAL; MICE; MICE, INBRED BALB C; TULAREMIA; VACCINES, ATTENUATED; VIRULENCE;

EID: 77957736080     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00192-10     Document Type: Article

References (47)

1. Alibek, K. 1999. Biohazard: the chilling true story of the largest covert biological weapons program in the world, told from the inside by the man who ran it. Random House, Inc., New York, NY.
2. Bakshi, C. S., M. Malik, K. Regan, J. A. Melendez, D. W. Metzger, V. M. Pavlov, and T. J. Sellati. 2006. Superoxide dismutase B gene (sodB)-deficient mutants of Francisella tularensis demonstrate hypersensitivity to oxidative stress and attenuated virulence. J. Bacteriol. 188:6443-6448.
3. Bakshi, C. S., M. Malik, M. Mahawar, G. S. Kirimanjeswara, K. R. Hazlett, L. E. Palmer, M. B. Furie, R. Singh, J. A. Melendez, T. J. Sellati, and D. W. Metzger. 2008. An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine 26:5276-5288.
4. Baron, S. D., R. Singh, and D. W. Metzger. 2007. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion. Infect. Immun. 75:2152-2162.
5. Chamberlain, R. E. 1965. Evaluation of live tularemia vaccine prepared in a chemically defined medium. Appl. Microbiol. 13:232-235.
6. Christopher, G. W., T. J. Cieslak, J. A. Pavlin, and E. M. Eitzen, Jr. 1997. Biological warfare. A historical perspective. JAMA 278:412-417.
7. Cong, Y., J. J. Yu, M. N. Guentzel, M. T. Berton, J. Seshu, K. E. Klose, and B. P. Arulanandam. 2009. Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (ΔiglB) induces protective immunity against homotypic and heterotypic challenge. Vaccine 27:5554-5561.
8. Conlan, J. W., H. Shen, A. Webb, and M. B. Perry. 2002. Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop various degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine 20:3465-3471.
9. Conlan, J. W., H. Shen, I. Golovliov, C. Zingmark, P. C. Oyston, W. Chen, R. V. House, and A. Sjostedt. 2009. Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization. Vaccine 28:1824-1831.
10. Conlan, W. J., and P. C. Oyston. 2007. Vaccines against Francisella tularensis. Ann. N. Y. Acad. Sci. 1105:325-350.
11. Dennis, D. T., T. V. Inglesby, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. D. Fine, A. M. Friedlander, J. Hauer, M. Layton, S. R. Lillibridge, J. E. McDade, M. T. Osterholm, T. O'Toole, G. Parker, T. M. Perl, P. K. Russell, and K. Tonat. 2001. Tularemia as a biological weapon: medical and public health management. JAMA 285:2763-2773.
12. Feldman, K. A., R. E. Enscore, S. L. Lathrop, B. T. Matyas, M. McGuill, M. E. Schriefer, D. Stiles-Enos, D. T. Dennis, L. R. Petersen, and E. B. Hayes. 2001. An outbreak of primary pneumonic tularemia on Martha's Vineyard. N. Engl. J. Med. 345:1601-1606.
13. Fulop, M., P. Mastroeni, M. Green, and R. W. Titball. 2001. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine 19:4465-4472.
14. Golovliov, I., M. Ericsson, L. Akerblom, G. Sandstrom, A. Tarnvik, and A. Sjostedt. 1995. Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis. Vaccine 13:261-267.
15. Griffin, K. F., P. C. Oyston, and R. W. Titball. 2007. Francisella tularensis vaccines. FEMS Immunol. Med. Microbiol. 49:315-323.
16. Harris, S. 1992. Japanese biological warfare research on humans: a case study of microbiology and ethics. Ann. N. Y. Acad. Sci. 666:21-52.
17. Hood, A. M. 1977. Virulence factors of Francisella tularensis. J. Hyg. (Lond.) 79:47-60.
18. Hornick, R. B., A. T. Dawkins, H. T. Eigelsbach, and J. J. Tulis. 1966. Oral tularemia vaccine in man. Antimicrob. Agents Chemother. 6:11-14.
19. Hornick, R. B., and H. T. Eigelsbach. 1966. Aerogenic immunization of man with live tularemia vaccine. Bacteriol. Rev. 30:532-538.
20. Horwitz, M. A., G. Harth, B. J. Dillon, and S. Maslesa-Galic. 2000. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. U. S. A. 97:13853-13858.
21. Horwitz, M. A., and G. Harth. 2003. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun. 71:1672-1679.
22. Huntley, J. F., P. G. Conley, D. A. Rasko, K. E. Hagman, M. A. Apicella, and M. V. Norgard. 2008. Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. Infect. Immun. 76:3664-3671.
23. Jia, Q., B. Y. Lee, D. L. Clemens, R. A. Bowen, and M. A. Horwitz. 2009. Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized type A F. tularensis. Vaccine 27:1216-1229.
24. Kuolee, R., G. Harris, J. W. Conlan, and W. Chen. 2007. Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis. Vaccine 25:3781-3791.
25. Larsson, P., P. C. Oyston, P. Chain, M. C. Chu, M. Duffield, H. H. Fuxelius, E. Garcia, G. Halltorp, D. Johansson, K. E. Isherwood, P. D. Karp, E. Larsson, Y. Liu, S. Michell, J. Prior, R. Prior, S. Malfatti, A. Sjostedt, K. Svensson, N. Thompson, L. Vergez, J. K. Wagg, B. W. Wren, L. E. Lindler, S. G. Andersson, M. Forsman, and R. W. Titball. 2005. The complete genome sequence of Francisella tularensis, the causative agent of tularemia. Nat. Genet. 37:153-159.
26. Li, J., C. Ryder, M. Mandal, F. Ahmed, P. Azadi, D. S. Snyder, R. D. Pechous, T. Zahrt, and T. J. Inzana. 2007. Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS. Microbiology 153:3141-3153.
27. LoVullo, E. D., L. A. Sherrill, L. L. Perez, and M. S. Pavelka, Jr. 2006. Genetic tools for highly pathogenic Francisella tularensis subsp. tularensis. Microbiology 152:3425-3435.
28. Maier, T. M., A. Havig, M. Casey, F. E. Nano, D. W. Frank, and T. C. Zahrt. 2004. Construction and characterization of a highly efficient Francisella shuttle plasmid. Appl. Environ. Microbiol. 70:7511-7519.
29. McCrumb, F. R. 1961. Aerosol infection of man with Pasteurella tularensis. Bacteriol. Rev. 25:262-267.
30. Pavlov, V. M., A. N. Mokrievich, and K. Volkovoy. 1996. Cryptic plasmid pFNL10 from Francisella novicida-like F6168: the base of plasmid vectors for Francisella tularensis. FEMS Immunol. Med. Microbiol. 13:253-256.
31. Pechous, R. D., T. R. McCarthy, N. P. Mohapatra, S. Soni, R. M. Penoske, N. H. Salzman, D. W. Frank, J. S. Gunn, and T. C. Zahrt. 2008. A Francisella tularensis Schu S4 purine auxotroph is highly attenuated in mice but offers limited protection against homologous intranasal challenge. PLoS One 3:e2487.
32. Qin, A., D. W. Scott, J. A. Thompson, and B. J. Mann. 2009. Identification of an essential Francisella tularensis subsp. tularensis virulence factor. Infect. Immun. 77:152-161.
33. Raynaud, C., K. L. Meibom, M. A. Lety, I. Dubail, T. Candela, E. Frapy, and A. Charbit. 2007. Role of the wbt locus of Francisella tularensis in lipopolysaccharide O-antigen biogenesis and pathogenicity. Infect. Immun. 75:536-541.
34. Rozen, S., and H. J. Skaletsky. 2000. Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 132:365-386.
35. Salomonsson, E., K. Kuoppa, A. L. Forslund, C. Zingmark, I. Golovliov, A. Sjostedt, L. Noppa, and A. Forsberg. 2009. Reintroduction of two deleted virulence loci restores full virulence to the live vaccine strain of Francisella tularensis. Infect. Immun. 77:3424-3431.
36. Sandstrom, G., S. Lofgren, and A. Tarnvik. 1988. A capsule-deficient mutant of Francisella tularensis LVS exhibits enhanced sensitivity to killing by serum but diminished sensitivity to killing by polymorphonuclear leukocytes. Infect. Immun. 56:1194-1202.
37. Saslaw, S., H. T. Eigelsbach, J. A. Prior, H. E. Wilson, and S. Carhart. 1961. Tularemia vaccine study. II. Respiratory challenge. Arch. Intern. Med. 107: 702-714.
38. Saslaw, S., H. T. Eigelsbach, H. E. Wilson, J. A. Prior, and S. Carhart. 1961. Tularemia vaccine study. I. Intracutaneous challenge. Arch. Intern. Med. 107:689-701.
39. Sebastian, S., S. T. Dillon, J. G. Lynch, L. T. Blalock, E. Balon, K. T. Lee, L. E. Comstock, J. W. Conlan, E. J. Rubin, A. O. Tzianabos, and D. L. Kasper. 2007. A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity. Infect. Immun. 75:2591-2602.
40. Sjostedt, A., G. Sandstrom, and A. Tarnvik. 1992. Humoral and cell-mediated immunity in mice to a 17-kilodalton lipoprotein of Francisella tularensis expressed by Salmonella typhimurium. Infect. Immun. 60:2855-2862.
41. Sjostedt, A. 2007. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann. N. Y. Acad. Sci. 1105:1-29.
42. Sorokin, V. M., N. V. Pavlovich, and L. A. Prozorova. 1996. Francisella tularensis resistance to bactericidal action of normal human serum. FEMS Immunol. Med. Microbiol. 13:249-252.
43. Su, J., J. Yang, D. Zhao, T. H. Kawula, J. A. Banas, and J. R. Zhang. 2007. Genome-wide identification of Francisella tularensis virulence determinants. Infect. Immun. 75:3089-3101.
44. Thomas, R. M., R. W. Titball, P. C. Oyston, K. Griffin, E. Waters, P. G. Hitchen, S. L. Michell, I. D. Grice, J. C. Wilson, and J. L. Prior. 2007. The immunologically distinct O antigens from Francisella tularensis subspecies tularensis and Francisella novicida are both virulence determinants and protective antigens. Infect. Immun. 75:371-378.
45. Tullius, M. V., G. Harth, S. Maslesa-Galic, B. J. Dillon, and M. A. Horwitz. 2008. A replication-limited recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG. Infect. Immun. 76:5200-5214.
46. Twine, S., M. Bystrom, W. Chen, M. Forsman, I. Golovliov, A. Johansson, J. Kelly, H. Lindgren, K. Svensson, C. Zingmark, W. Conlan, and A. Sjostedt. 2005. A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine. Infect. Immun. 73:8345-8352.
47. Weiss, D. S., A. Brotcke, T. Henry, J. J. Margolis, K. Chan, and D. M. Monack. 2007. In vivo negative selection screen identifies genes required for Francisella virulence. Proc. Natl. Acad. Sci. U. S. A. 104:6037-6042.